|
As if he weren't busy enough as Editor-in-Chief of the Journal of Clinical Microbiology, Alex is on the ballot for President-Elect of ASM. Best wishes, Alex!
0 Comments
More information can be found at the following links:
https://www.bidmc.org/about-bidmc/collaboration https://www.dana-farber.org/about/partners-affiliates/dana-farber-beth-israel-deaconess-cancer-collaboration https://www.bostonglobe.com/2023/10/16/opinion/cancer-dana-farber-beth-israel-mass-general-brigham/ Learning to Count the Hard Way: Measuring Diversity in the Microbiome and Beyond
presented by: Ramy Arnaout, MD, DPhil Dr. Arnaout is the Associate Director of the Clinical Microbiology Laboratories at Beth Israel Deaconess Medical Center and Associate Professor of Pathology at Harvard Medical School and President of the ASM Northeast Branch. His research lies at the intersection of computation, immunology, and infectious disease and brings mathematical and physics-based approaches to bear on several problems, including deciphering large-scale antibody and T-cell receptor immunomes. Today’s talk is about a key tool in the toolkit: measuring diversity in complex systems. Learning to do so led the laboratory on an enlightening (and humbling) journey from immunomes to information theory to microbiomes and beyond. Staking out new territory on the ribosome for antibiotic development presented by: James E. Kirby, MD, D(ABMM) Dr. Kirby is an NIH-funded Principal Investigator in the Experimental Pathology Division of Beth Israel Deaconess Medical Center, Boston, MA, Director of the Clinical Microbiology Laboratory at BIDMC; Program Director of the Medical Microbiology Fellowships at BIDMC; and Professor of Pathology at Harvard Medical School, Boston, MA. He was past president of the Northeast Branch-ASM from 2009-2012. Dr. Kirby will talk about his collaborative efforts to develop antibiotics targeting gram-negative ESKAPE pathogens. He will discuss the emerging threat from such pathogens; the difficulty in developing new drugs to treat them; and the activity; action; and goals and strategies for development of rediscovered natural products. Registration Colette was busy during her 3-month clinical microbiology rotation at BIDMC prior to moving on to a CPEP fellowship at UCLA. Here manuscript validating the performance of the Abbott Alinity m STI test (a quadriplex assay simultaneously detecting Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium inclusive of sampling and internal controls) was recently published in Practical Laboratory Medicine. We are delighted to be part of the early launch of several clinical microbiology careers and wish Dr. Matysiak well in her fellowship training and beyond!
Here is the reference and full text link: Matysiak C, Cheng A, Kirby JE. Evaluation of the Abbott Alinity m STI assay for diagnosis of the primary causes of sexually transmitted infections in the United States. Pract Lab Med. 2023 Aug 22;36:e00332. doi: 10.1016/j.plabm.2023.e00332. PMID: 37705589; PMCID: PMC10495529. While reviewing SARS-CoV-2 literature, serendipitously came across a new MexRXiv posting by the Arnaout laboratory titled: "Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR Repertoires." Fascinating contribution to the understanding our immune response to this infection. Congratulations, Dr. Arnaout!
On the "Susceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinations"!!! Way to go Dr. Brennan-Krohn
Just out our recently posted pre-print in MedRXiv --> real-world data to inform regulatory pathways for SARS-CoV-2 PCR and antigen tests from our work led by Clin Micro Attending, Ramy Arnaout, sponsored by the Reagan-Udall foundation. Check out the data yourself - how any of large number of metadata influences SARS-CoV-2 testing results. An example below is a plot of viral loads by variant and whether patients were sick or well.  |
RSS Feed